Jonathon Whitehouse
17Patents
4h-index
12Co-inventors
53Inventor score
Filing activity: Mar 16, 2007 → Aug 17, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11185508B2 | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension | Human Necessities | 5 | Active |
| US11166919B2 | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | Human Necessities | 5 | Active |
| US11077067B2 | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | Human Necessities | 5 | Active |
| US11141380B2 | Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products | Human Necessities | 4 | Active |
| US11026892B2 | Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products | Human Necessities | 4 | Active |
| US9700508B2 | Pharmaceutical compositions comprising hydromorphone and naloxone | Human Necessities | 1 | Active |
| US11779540B2 | Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products | Human Necessities | 1 | Active |
| US9814710B2 | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | Human Necessities | 1 | Active |
| US9034373B2 | Pharmaceutical spheroids | Human Necessities | 0 | Active |
| US12350372B2 | Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products | Human Necessities | 0 | Active |
| US10258616B2 | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | Human Necessities | 0 | Active |
| US12257351B2 | Minimizing aeration of suspensions during in-line mixing | Human Necessities | 0 | Active |
| US12201726B2 | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension | Human Necessities | 0 | Active |
| US11931464B2 | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | Human Necessities | 0 | Active |
| US9820983B2 | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | Human Necessities | 0 | Active |
| US9271940B2 | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | Human Necessities | 0 | Active |
| US12208160B2 | Pharmaceutical compositions comprising coated API | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.